Table 1.

Patient baseline characteristics

CharacteristicsValue
Total enrolled80
Age (yr), mean (SD)71.3±10.9
Sex
 Male61 (76%)
 Female19 (24%)
Race
 White53 (66%)
 Asian11 (14%)
 Black10 (13%)
 Unknown/not reported4 (5%)
 American Indian/Alaska Native1 (1%)
 More than one race/multiracial1 (1%)
Ethnicity
 Non-Hispanic77 (96%)
 Hispanic2 (3%)
 Unknown/not reported1 (1%)
Cause of CKD
 DM type 263 (79%)
 Other17 (21%)
Medical history
 CHF20 (25%)
 CAD26 (33%)
 Hypertension77 (96%)
 Stroke17 (21%)
 History of malignancy6 (8%)
eGFR, n (%)
 0 to ≤15 ml/min15 (19%)
 >15 to ≤30 ml/min34 (43%)
 >30 to ≤45 ml/min31 (39%)
Years of known kidney disease6.8±7.4
Body mass index, n (%)
 ≤25 kg/m214 (18%)
 >25 to ≤30 kg/m233 (41%)
 >30 to ≤35 kg/m221 (26%)
 >35 kg/m212 (15%)
Fasting glucose (mg/dl)160.2±59.4
HbA1c (%)7.2±1.5
Serum fructosamine, µmol/L304.1±57.3
Medications
 Insulin
 Insulin, short acting only10 (13%)
 Insulin, long acting only14 (18%)
 Insulin, short and long acting18 (23%)
 Sulfonylureas22 (28%)
 Insulin and sulfonylureas8 (10%)
 Other oral hypoglycemic agents other than SU and GLP27 (34%)
 GLP-1 receptor agonists10 (13%)
  • Adapted from Presswala et al. (10). DM, diabetes mellitus; CHF, congestive heart failure; CAD, coronary artery disease; HbA1c, hemoglobin A1c; SU, sulfonylureas; GLP, glucagon-like peptide-1 receptor agonists; GLP-1, glucagon-like peptide 1.